Angels for Life Sciences (A4LS) is represented by a team of professionals who collectively represent a wealth of experience in the life sciences sector and the angel investment market.
Simon is a business professional with two decades’ experience of creating and developing innovative life science businesses. Before joining Karus as the Company's first CEO in 2006, he was Director of Business Development at Ablynx NV (Ghent, Belgium), where he was responsible for securing a number of research, development and licensing agreements with major pharmaceutical companies including Pfizer and Novartis. He also played a key role in Ablynx's development from early-stage to one of Europe's most promising antibody fragment companies.
Prior to Ablynx, Simon was Director of Business Development at Active Biotech AB (Lund, Sweden), where he spun-out the molecular evolution company, Isogenica Ltd (Cambridge, UK), later joining the spin-out as Vice President of Business Development. Simon has held other key commercial appointments at Actinova Ltd (Cambridge UK), and Actigen Ltd (Cambridge, UK). He has also occupied senior commercial roles at the Health Protection Agency (Salisbury, UK) and within the Jasmin group of companies. Simon has a medicinal chemistry degree, a life science PhD and an executive MBA from Loughborough University Business School.
Dr Will West is CEO of CellCentric, a Cambridge-based drug discovery company. Will completed his PhD in immunology and virology in 1992, sponsored by Unilever (UniPath). He then held a post-doctoral position at the National Institute of Biological Standards and Control (NIBSC) before joining Procter & Gamble Healthcare, responsible for clinical development in multiple therapeutic areas, working in Europe, the US, South Africa and China.
Will holds a Masters degree in Clinical Research as well as an MBA from London Business School. In 2012 he was appointed to the Council of the BBSRC, the UK’s leading funder of bioscience research (over £500m a year). In 2013 Will was elected to the Board of the BioIndustry Association (BIA) and sits on the Audit Committee. He also is a non-executive Director of PlaqueTec, a cardiovascular company based at the Papworth Hospital.
Andy Richards is an Entrepreneur and Angel Investor specialising in life sciences. He is currently Chairman of Altacor, Abcodia, Novacta and Ixico, Co-Chair of Cambridge Temperature Concepts, a Non-Executive Director of Arecor and PsychologyOn-line and is founder and special advisor to Vectura plc. In addition, he is a Non-Executive Director of Cancer Research Technologies (the commercial arm of CR-UK) and Babraham Bioscience Technologies, is a member of the BBSRC Council and a Trustee of the British Science Association. He is a founder member of Cambridge Angels and an advisor to several Venture Capital Funds, Private Equity Funds and Corporate Venture Funds.
Andy is a Cambridge graduate with a PhD in enzyme chemistry who spent his early career with ICI (now AstraZeneca) and with PA Technology. He was a founder of Chiroscience and an executive director through to the sale to Celltech in 1999. Andy has a track record as a founder and active investor in more than 20 innovative healthcare and life-science companies over the last 12 years including companies that are have exited such as Arakis, Cambridge Biotechnology Ltd, Sirus, Daniolabs, Biowisdom, Geneservice, Pharmakodex and Clinical Force.
Whilst working with entrepreneurs in 1999 in a start-up consultancy and small fund Eileen started consulting for Oxford Innovation, joining as part of the Projects Team in early 2001. Eileen project managed several European projects relating to business development and commercialisation for SMEs. Since 2003 Eileen has managed all of Oxford Innovation’s angel networks, the Oxford Investment Opportunity Networks Ltd; being instrumental in taking the TVIN network from pump-prime funding to self-funding status. Eileen led the due diligence negotiations for OION to establish a Co-investment Programme with a leading corporate bank in 2008. A format that part inspired for the £100m Angel CoFund established under Capital for Enterprise where OION Ltd was one of the partners that worked with Capital for Enterprise in the bid to the Regional Growth Fund. Well known within the investment community Eileen is also National Investor Relations Manager for access to finance for Growth Accelerator programme, supporting current and developing new angel groups, syndicates and angel clubs, Eileen has a BSc (Hons) degree and is an ILM qualified business coach.
Ian was the founder and chief executive of Pharmaceutical Profiles, a successful spin-out company from Nottingham University specializing in the clinical evaluation of drug delivery systems. He has over 250 publications and has served as an expert scientist for the FDA. He is a recipient of the CRS career achievement award in oral drug delivery and is an eminent fellow of the UK Academy of Pharmaceutical Scientists. In a long career commercializing science, he was also the cofounder of R5 Pharmaceuticals, Zysis and BioCity Nottingham. In addition to several Board roles, Ian currently consults for over 30 pharmaceutical and biotech companies on drug development and commercialization issues.
Keith's main activity outside LBS is helping entrepreneurs to build, buy and sell ventures. Keith is Chairman of Servebase Ltd (Payments processing) and Fern & Bracken Trading Limited (Secured Lending via Octopus Investments) and Non-Executive at Vitesse Media plc (Publishing) and Feedzai S.A. (Enterprise Software). He is advisor/investor to a number of other ventures.
Inga is an Associate in the Healthcare Ventures team at Imperial Innovations, specialising in investments across medical devices, therapeutics, diagnostics, and healthcare, including digital health. She is currently a Director at Puridify and Ieso Digital Health and a board observer at Veryan Medical. Previously she worked in business development and technology transfer at the London Bioscience Innovation Centre/Royal Veterinary College in London. She completed a DPhil and MSc in Neuroscience from the University of Oxford, sponsored by the Wellcome Trust, developing translational models of disease. Her first degree was Natural Sciences from the University of Cambridge